When using CHM1 CD8 T cells in combination with XVir-N-31, an increase of tumor cell killing was measured already 12h after addition of T cells with an increase of killing activity in a MOI/dose-dependent manner (Figures 3D–F). This evidence concerns the gene CD8A and neoplasm.